![\"\"](\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/11\/CurveBiosciences_RitishPatnaik_DSC_7221-970.jpg\")
<\/p>\n <\/p>\n
Curve Biosciences Founder and CEO Ritish Patnaik [Photo: Curve Biosciences]<\/p>\n
A Plano-born biotech founder has returned to North Texas to establish the headquarters for his company, Curve Biosciences, at Pegasus Park, the nationally recognized life science and biotech innovation hub in Dallas.<\/strong><\/p>\n Curve announced it has raised $40 million in funding led by Luma Group with participation from First Spark Ventures, Techas Capital, Micah Spear, Civilization Ventures, LifeX Ventures, Incite, Mintaka VC, NZVC, and others.<\/p>\n The company said the funding will advance the clinical validation and commercialization of its Whole-Body Intelligence platform, with a goal of \u201ctransforming\u201d chronic disease monitoring.<\/p>\n Curve\u2019s founder and CEO, Ritish Patnaik, left Texas to pursue his doctorate from Stanford University on the West Coast, the company said, but decided to open Curve\u2019s headquarters back near his home turf.<\/p>\n \u201cChronic diseases are on the rise, and healthcare costs are skyrocketing as a result. We need to improve patient monitoring to realize the positive impacts of breakthroughs like GLP-1s,\u201d Patnaik said in a statement. \u201cTo raise the standard of chronic disease monitoring, we are now introducing the first Whole-Body Intelligence platform with AI models trained on our Whole-Body Atlas and fueled by our Whole-Body Blood Tests. We\u2019ve paired this platform with a successful executive team to realize our vision for proactive, personalized chronic care that minimizes suffering.\u201d<\/p>\n Curve Biosciences, which calls itself the \u201cWhole-Body Intelligence\u201d company, has created what it calls \u201cthe first molecular blueprint of the human body\u201d with its Whole-Body Atlas\u2014said to be the world\u2019s largest collection of manually curated tissue samples characterized by organ and disease state. By returning to \u201ctissue-level biological truth,\u201d the company says it\u2019s creating simple, proactive Whole-Body Blood Tests that anticipate chronic disease, guide treatment, and align patients, insurers, pharma, and doctors.<\/p>\n More on Curve founder and leadership<\/p>\n Born and raised in Plano, Patnaik attended Plano public schools and the University of North Texas before leaving in 2012 for Stanford. At the time of Patnaik\u2019s graduation from Stanford, DFW lacked biotech infrastructure, presenting no viable path to build or fund a biotech company, the founder said.<\/p>\n Flash forward to today. North Texas has established itself as a leading hub for biotech innovation, and the 26-acre Pegasus Park<\/a> campus is home to more than 885,000 square feet of office and lab space, including 37,000 square feet dedicated to BioLabs Pegasus Park<\/a>, designed for startups, and 135,000 more for Bridge Labs<\/a>, for those that graduate into the next phase of funding and growth.<\/p>\n Curve\u2019s executive team includes, per the company:<\/p>\n \u00a0 Curve said it will provide more information on its Whole-Body Intelligence platform and chronic disease pipeline in the coming months.<\/p>\n \u201cWe believe Curve\u2019s Whole-Body Intelligence platform represents the next frontier in clinical testing, with the potential to fundamentally reshape how we monitor and manage chronic disease,\u201d said Themasap Khan, PhD, co-founder and partner at Luma Group. \u201cBy anchoring in human tissue data, Curve is building a clinically actionable platform with clear reimbursement potential and massive market applicability.\u201d<\/p>\n Don\u2019t miss what\u2019s next. Subscribe\u00a0to\u00a0Dallas\u00a0Innovates.<\/p>\n Track Dallas-Fort Worth\u2019s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.<\/p>\n \u00a0<\/p>\n \tR E A D\u00a0\u00a0 N E X T\t<\/p>\n The new center at Bridge Labs will train the workforce powering North Texas\u2019 biotech boom\u2014helping startups speed therapies, vaccines, and breakthrough biologics from lab bench to patients. Funded in part by Lyda Hill Philanthropies, the National Center for Therapeutics Manufacturing Satellite Campus is set to open this summer.<\/p>\n<\/li>\n Founded in 2012, Universal DX is focused on “cracking cancer\u2019s code” via its multi-omics and machine learning models. Starting with colorectal cancer, it’s building a “multi-cancer platform” that can ID the unique DNA regions associated with different types of cancers.<\/p>\n<\/li>\n Backed by a National Science Foundation grant, the project\u2019s key innovation is WHEELCOM\u2014a device that captures wheelchair movement data to help engineers design smarter, more inclusive buildings.<\/p>\n<\/li>\n The study of data from past storms includes researchers from multiple universities as well as international partners from hurricane-prone regions including the Bahamas, Jamaica, and Costa Rica.<\/p>\n<\/li>\n Part of the 2025 iC\u00b3 Life Science & Healthcare Innovation Summit to be held September 16-17 in Dallas, the showcase pitch event is designed to connect university researchers with potential investors, industry executives, and strategic partners. This is the first year the showcase has expanded beyond Texas.<\/p>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"Curve Biosciences Founder and CEO Ritish Patnaik [Photo: Curve Biosciences] A Plano-born biotech founder has returned to North…\n","protected":false},"author":3,"featured_media":372889,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5135],"tags":[179484,5229,179485,51056,179486,179487,179488,1596,179489,11787,179490,179491,179492,179493,179494,179495,39887,179496,179497,179498,3972,179499,358,3187,67,586,132,5230,148314,68,2969,179500],"class_list":{"0":"post-372888","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-dallas","8":"tag-alice-chen","9":"tag-america","10":"tag-biolabs-pegasus-park","11":"tag-chronic-diseases","12":"tag-chuba-oyolu","13":"tag-civilization-ventures","14":"tag-curve-biosciences","15":"tag-dallas","16":"tag-first-spark-ventures","17":"tag-headquarters","18":"tag-incite","19":"tag-lifex-ventures","20":"tag-micah-spear","21":"tag-mintaka-vc","22":"tag-nathan-hunkapiller","23":"tag-nzvc","24":"tag-pegasus-park","25":"tag-plano-public-schools","26":"tag-ritish-patnaik","27":"tag-shan-wang","28":"tag-stanford-university","29":"tag-techas-capital","30":"tag-texas","31":"tag-tx","32":"tag-united-states","33":"tag-united-states-of-america","34":"tag-unitedstates","35":"tag-unitedstatesofamerica","36":"tag-university-of-north-texas","37":"tag-us","38":"tag-usa","39":"tag-whole-body-intelligence"},"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/372888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=372888"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/372888\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/372889"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=372888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=372888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=372888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n\u2018Next frontier in clinical testing\u2019<\/p>\n\n
![\"\"](\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/07\/NCTM_team_970.jpg\")
<\/a><\/p>\n![\"\"](\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/07\/Bridge-Labs-at-Pegasus-Park-is-at-right-with-the-campuss-18-story-office-tower-on-the-left-Photo-Mau.jpeg\")
<\/a><\/p>\n![\"\"](\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/07\/UTA-WheelchairAccess-970.jpg\")
<\/a><\/p>\n![\"\"](\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/07\/UTA-hurricane-research-970x464.jpg\")
<\/a><\/p>\n![\"\"](\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/08\/BioNTX-concept-tech-transfer_iStock-1878762861.jpg\"){kind=spacer}
<\/a><\/p>\n